Scynexis (SCYX) Shares Outstanding (Weighted Average) (2013 - 2026)
Scynexis (SCYX) reported Shares Outstanding (Weighted Average) of $51.0 million for Q1 2026, up 3.08% on a YoY basis from $49.4 million in Q1 2025, and up 2.05% quarter-over-quarter from $49.9 million in Q4 2025.
Scynexis (SCYX) Shares Outstanding (Weighted Average) (2013 - 2026) Analysis & Trends
Scynexis has reported Shares Outstanding (Weighted Average) for 14 years, with the latest figure at $51.0 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.08% year-over-year to $51.0 million; the trailing twelve-month figure through Mar 2026 stood at $51.0 million (up 3.08% YoY), and the FY2025 full-year result was $49.9 million, up 2.93% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $51.0 million, up from $49.9 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $51.0 million in Q1 2026, with the low at $32.1 million in Q1 2022.
- Historically, Shares Outstanding (Weighted Average) has averaged $46.4 million across 5 years, with a median of $48.2 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) jumped 61.51% — and 2024, when it advanced 1.02%.
- Scynexis' Shares Outstanding (Weighted Average) stood at $42.6 million in 2022, then advanced by 12.29% to $47.9 million in 2023, then rose by 1.38% to $48.5 million in 2024, then rose by 2.93% to $49.9 million in 2025, then grew by 2.05% to $51.0 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $51.0 million (Q1 2026), $49.9 million (Q4 2025), and $49.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1.16 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 422.10 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 43.50 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 5.02 Bn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 100.50 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 497.70 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 166.20 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 228.36 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 64.74 Mn |
| 10 | Scynexis | 225.23 Mn | 165.97 Mn | - | 50.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.96 Mn |
| Dec 31, 2025 | 49.93 Mn |
| Sep 30, 2025 | 49.90 Mn |
| Jun 30, 2025 | 49.75 Mn |
| Mar 31, 2025 | 49.44 Mn |
| Dec 31, 2024 | 48.51 Mn |
| Sep 30, 2024 | 48.46 Mn |
| Jun 30, 2024 | 48.51 Mn |
| Mar 31, 2024 | 48.25 Mn |
| Dec 31, 2023 | 47.85 Mn |
| Sep 30, 2023 | 47.89 Mn |
| Jun 30, 2023 | 47.80 Mn |
| Mar 31, 2023 | 47.76 Mn |
| Dec 31, 2022 | 42.61 Mn |
| Sep 30, 2022 | 40.97 Mn |
| Jun 30, 2022 | 37.65 Mn |
| Mar 31, 2022 | 32.05 Mn |
| Dec 31, 2021 | 26.38 Mn |
| Sep 30, 2021 | 26.15 Mn |
| Jun 30, 2021 | 26.02 Mn |